Analysts Are Optimistic We'll See A Profit From Captor Therapeutics Spolka Akcyjna (WSE:CTX)

Captor Therapeutics Spolka Akcyjna (WSE:CTX) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The zł242m market-cap company’s loss lessened since it announced a zł71m loss in the full financial year, compared to the latest trailing-twelve-month loss of zł41m, as it approaches breakeven. As path to profitability is the topic on Captor Therapeutics Spolka Akcyjna's investors mind, we've decided to gauge market sentiment. We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.

View our latest analysis for Captor Therapeutics Spolka Akcyjna

Captor Therapeutics Spolka Akcyjna is bordering on breakeven, according to the 3 Polish Biotechs analysts. They anticipate the company to incur a final loss in 2024, before generating positive profits of zł800k in 2025. The company is therefore projected to breakeven around 12 months from now or less. At what rate will the company have to grow in order to realise the consensus estimates forecasting breakeven in under 12 months? Using a line of best fit, we calculated an average annual growth rate of 71%, which is extremely buoyant. Should the business grow at a slower rate, it will become profitable at a later date than expected.

Given this is a high-level overview, we won’t go into details of Captor Therapeutics Spolka Akcyjna's upcoming projects, however, bear in mind that typically a biotech has lumpy cash flows which are contingent on the product type and stage of development the company is in. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

One thing we’d like to point out is that Captor Therapeutics Spolka Akcyjna has no debt on its balance sheet, which is quite unusual for a cash-burning biotech, which typically has high debt relative to its equity. This means that the company has been operating purely on its equity investment and has no debt burden. This aspect reduces the risk around investing in the loss-making company.

Next Steps:

This article is not intended to be a comprehensive analysis on Captor Therapeutics Spolka Akcyjna, so if you are interested in understanding the company at a deeper level, take a look at Captor Therapeutics Spolka Akcyjna's company page on Simply Wall St. We've also put together a list of pertinent aspects you should further examine:

1. Historical Track Record: What has Captor Therapeutics Spolka Akcyjna's performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Captor Therapeutics Spolka Akcyjna's board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.